Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

NCT04626089 is registered in ClinicalTrials.gov with Laboratorios Silanes S.A. de C.V. as lead sponsor.

NCT NCT04626089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04626089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.
Lead sponsor
Laboratorios Silanes S.A. de C.V.
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2021
Completion date
February 28, 2021
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic syndrome, severe acute respiratory syndrome coronavirus 2, type 2 diabetes